<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LANTHANUM CARBONATE</span><br/>(lan-tha'num)<br/><span class="topboxtradename">Fosrenol<br/></span><b>Classifications:</b> <span class="classification">electrolyte and water balance agent</span>; <span class="classification">phosphate binder</span><br/><b>Prototype: </b>Sevelamer Hydrochloride<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg chewable tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Lanthanum is used for the management of hyperphosphatemia in patients with end-stage renal disease; it is a calcium-/aluminum-free
         phosphate binding agent. It has a higher affinity for binding to phosphate than calcium or aluminum. Low systemic absorption
         minimizes the risk of aluminum intoxication and hypercalcemia.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lanthanum decreases phosphate absorption from the diet. Dietary phosphate bound to lanthanum carbonate is excreted in the
         feces and results in lowering of serum phosphate and urinary excretion of phosphate.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Reduce serum phosphate levels in patients with end-stage renal disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Prior hypersensitivity to lanthanum carbonate; pregnancy (category C); children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Bowel obstruction, Crohn's disease, acute peptic ulcer, ulcerative colitis; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hyperphosphatemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250500 mg t.i.d. with or immediately after meals; may titrate up every 23 wk in increments of 750 mg/d to achieve
               acceptable serum phosphate levels (max: 3750 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with or immediately after a meal.</li>
<li>Tablets must be chewed completely before swallowing. Whole tablets should not be swallowed.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS<b></b> 			:</span> Headache. <span class="typehead">CV<b></b> 			:</span> Hypotension. <span class="typehead">GI<b></b> 			:</span> <span class="speceff-common">Nausea, vomiting, diarrhea</span> <i>,</i> abdominal pain, constipation. <span class="typehead">Respiratory<b></b> 			:</span> Bronchitis, rhinitis. <span class="typehead">Other<b></b> 			:</span> Dialysis graft occlusion. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption<b></b> 			:</span> Minimal absorption from GI tract. <span class="typehead">Metabolism<b></b> 			:</span> Not metabolized. <span class="typehead">Elimination<b></b> 			:</span> Excreted in feces. <span class="typehead">Half-Life:</span> 53 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for dialysis graft occlusion, as lanthanum therapy may increase occlusion risk.</li>
<li>Lab tests: serum phosphate levels during dosage titration and regularly throughout treatment; periodic serum calcium, bicarbonate,
            and chloride.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Chew chewable tablets completely, then swallow.</li>
<li>Report promptly any of the following: headache, drowsiness, dizziness, fainting, confusion, irritability, nausea, vomiting,
            or loss of appetite.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>